Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc. (NBIX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Overview: Neurocrine is a neuroscience-focused biopharmaceutical company. Its primary commercial product is INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea. In December 2024, the company launched CRENESSITY (crinecerfont), a first-in-class treatment for classic congenital adrenal hyperplasia (CAH). The company operates as a single global business segment.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Revenues | $2,355.3 | $1,887.1 | $1,488.7 |
| Net Product Sales | $2,330.6 | $1,860.6 | $1,440.9 |
| INGREZZA Sales | $2,313.5 | $1,836.0 | $1,427.8 |
| Collaboration Revenues | $24.7 | $26.5 | $47.8 |
| Operating Income | $570.5 | $250.9 | $249.0 |
| Net Income | $341.3 | $249.7 | $154.5 |
| Diluted EPS | $3.29 | $2.47 | $1.56 |
| Operating Cash Flow | $595.4 | $389.9 | $339.4 |
| Cash & Marketable Securities | $1,815.6 | $1,719.1 | N/A |
| Working Capital | $1,217.0 | $952.2 | N/A |
Debt: The company settled its $169.8 million aggregate principal amount of 2024 Convertible Senior Notes in full in cash upon maturity in May 2024. There is no long-term debt outstanding as of December 31, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 24.8% to $2.36 billion, driven primarily by a 26.0% increase in INGREZZA net product sales to $2.31 billion. This growth reflects strong patient demand and improved gross-to-net dynamics.
- Profitability: Net income increased 36.7% to $341.3 million. Operating income more than doubled to $570.5 million.
- Expense Increases:
- R&D: Increased 29.4% to $731.1 million, driven by higher milestone payments ($71.7 million vs. $0.8 million in 2023) and increased payroll/facilities costs.
- SG&A: Increased 13.5% to $1.01 billion due to commercial expansion, pre-launch CRENESSITY activities, and a $14.0 million impairment charge on vacated leased office space.
- Non-Operating Items: A $138.4 million charge was recognized in 2024 related to the conversion of the 2024 Notes upon maturity, partially offset by increased interest income.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- CRENESSITY Launch: Successfully launched in December 2024 for CAH. Management expects to continue investing in commercialization.
- Pipeline Progress: Positive Phase 2 data announced for NBI-1117568 (schizophrenia) and osavampator (MDD). Phase 3 development for NBI-1117568 is expected in H1 2025. Phase 3 for osavampator was initiated in January 2025.
- Liquidity: Management believes existing capital resources and anticipated sales are sufficient for at least the next 12 months.
- Share Repurchases: Completed a $300 million accelerated share repurchase (ASR) program in February 2025, acquiring approximately 2.3 million shares.
Risks and Contingencies:
- Customer Concentration: Four customers represented approximately 93% of total product sales and 98% of accounts receivable in 2024.
- Regulatory & Pricing: INGREZZA qualified for the "small biotech exception" to Medicare price negotiation until 2027. However, the company is subject to the Medicare Part D manufacturer discount program, which may impact revenues.
- Leadership Transition: Founder Kevin Gorman retired as CEO in October 2024; Kyle Gano succeeded him.
- Collaboration Milestones: Future payments of up to $17.7 billion are potential contingent liabilities based on milestone achievements with partners like Voyager, Takeda, and Nxera.
Investor Verification Checklist
- CRENESSITY Commercialization: Verify early sales uptake and reimbursement status for the newly launched CAH treatment.
- INGREZZA Gross-to-Net: Monitor the sustainability of the "improved gross-to-net dynamics" cited as a driver for 2024 sales growth.
- Customer Concentration: Assess the risk associated with reliance on four major distributors for 93% of sales.
- Medicare Part D Impact: Evaluate the financial impact of the new manufacturer discount program on INGREZZA margins.
- Pipeline Milestones: Track the initiation of Phase 3 trials for NBI-1117568 and osavampator, which trigger significant milestone payments to partners.
- Debt Settlement: Confirm the full extinguishment of the 2024 Convertible Notes and the associated $138.4 million charge impact on future comparability.